Noresmea (Norethisterone Acetate, Estradiol)

Norethisterone acetate acts as a progestogen, while estradiol provides estrogenic activity. Together they suppress the hypothalamic‑pituitary‑ovarian axis, preventing the luteinising hormone surge that triggers ovulation. The progestogen also thickens cervical mucus, and the estrogen stabilises the endometrium, creating conditions that reduce the chance of fertilisation and implantation.

The specific dosing regimen for Noresmea is determined by the prescribing healthcare professional based on the patient’s medical history and treatment goals. Patients should follow the prescriber’s instructions and the product label without deviation.

Noresmea is contraindicated during pregnancy because it is intended to prevent conception. If pregnancy occurs, the product should be discontinued and medical advice sought. Limited data are available for breastfeeding; therefore, the benefits and risks should be evaluated by a healthcare provider before use.

To order Noresmea, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and required import documentation.

Noresmea contains the same active components—norethisterone acetate and estradiol—as many other combined oral contraceptives, offering comparable efficacy in preventing pregnancy. Differences among products may lie in dosage strengths, tablet formulations, or additional inactive ingredients, which can affect tolerability, side‑effect profile, and patient preference.

Noresmea tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from excess moisture, heat, and direct sunlight to maintain potency throughout the shelf life.

Noresmea is taken orally, usually once daily at the same time each day. A typical regimen involves 21 consecutive days of tablet intake followed by a hormone‑free interval, during which withdrawal bleeding occurs. Exact instructions are provided by the prescribing clinician.

The most serious risks include venous thromboembolism, stroke, myocardial infarction, and severe allergic reactions such as anaphylaxis. These events are rare but require immediate medical attention. Patients with known risk factors—such as smoking, hypertension, or a history of clotting disorders—should discuss safety with their healthcare provider.

Noresmea is contraindicated in women with a history of thromboembolic disease, active liver disease, known or suspected breast cancer, uncontrolled hypertension, or in smokers over 35 years of age. It should also be avoided during pregnancy and in individuals with known hypersensitivity to any component of the tablet.